The Clinical Outcomes of Hyper-CVAD Treatment in Lymphoblastic Lymphoma
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Overall survival
研究概览
简要总结
Treatment outcomes of lymphoblastic lymphoma (LBL) have improved by the use of the regimens for acute lymphoblastic leukemia. Hyper-CVAD is one of the most effective treatments with high remission rate in acute lymphoblastic leukemia (ALL) and LBL. However, the treatment outcome of hyper-CVAD in LBL has reported only in small number of patients from single institution. The investigators conducted this study to evaluate the hyper-CVAD regimen based treatment in LBL.
详细描述
We will analyze treatment outcome of lymphoblastic lymphoma patients treated with hyper-CVAD regimen from 13 institutions in Korea. In all patients, hyper-CVAD was initial treatment. After achievement of response, patients either underwent hematopoietic stem cell transplantation (HSCT) or consolidation with hyper-CVAD.
研究设计
- 研究类型
- Observational
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age over 18 at diagnosis
- •Pathologically proven lymphoblastic lymphoma
排除标准
- •proven HIV infection
- •pretreatment with other regimens
结局指标
主要结局
Overall survival
时间窗: 3-year
Progression free survival
时间窗: 3-year
次要结局
- Response Rate(24 weeks)
研究者
Seong Hyun Jeong
Assistant professor
Ajou University School of Medicine